Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CTSL | P07711 | 4/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22462018 | 0.99 | TLR2 (0.53) | TLR2CTSSCTSLCTSBDDB1 | |
| SCHEMBL3334735 | 0.92 | TLR2 (0.53) | TLR2CTSSCTSLCTSBDDB1 | |
| SCHEMBL21777615 | 0.92 | CTSS (0.49) | TLR2CTSSCTSLCTSBDDB1 | |
| SCHEMBL29017562 | 0.92 | CTSS (0.49) | TLR2CTSSCTSLCTSBDDB1 | |
| SCHEMBL7818404 | 0.90 | TLR2 (0.53) | TLR2CTSSCTSLCTSBCTSK | |
| SCHEMBL4269314 | 0.89 | TLR2 (0.47) | TLR2CTSSCTSLCTSBDDB1 | |
| SCHEMBL25597451 | 0.88 | TLR2 (0.60) | TLR2CTSSCTSLCTSBCTSK | |
| SCHEMBL25198330 | 0.85 | CTSS (0.50) | TLR2CTSSCTSLCTSBCTSK | |
| SCHEMBL25198329 | 0.85 | CTSS (0.50) | TLR2CTSSCTSLCTSBCTSK | |
| SCHEMBL2913795 | 0.82 | CTSS (0.55) | TLR2CTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180530-B2 | Salt of phenylpropionamide derivative and preparation method therefor | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20200368309-A1 | USE OF KOR AGONIST IN COMBINATION WITH MOR AGONIST IN PREPARING DRUG FOR TREATING PAIN | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| US-20200331963-A1 | Salt of phenylpropionamide derivative and preparation method therefor | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20190144499-A1 | PHENYL PROPANAMIDE DERIVATIVE, AND MANUFACTURING METHOD AND PHARMACEUTICAL APPLICATION THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-16 | — | — | US | disclosed |
| EP-3466962-A1 | PHENYL PROPANAMIDE DERIVATIVE, AND MANUFACTURING METHOD AND PHARMACEUTICAL APPLICATION THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017211272-A1 | PHENYL PROPANAMIDE DERIVATIVE, AND MANUFACTURING METHOD AND PHARMACEUTICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2017-12-14 | — | — | WO | disclosed |
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-9321810-B2 | Uses of kappa opioid synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150152138-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8906859-B2 | Uses of kappa opioid synthetic peptide amides | Cera Therapeutics, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8486894-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8236766-B2 | Uses of synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20110212882-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180530-B2 | Salt of phenylpropionamide derivative and preparation method therefor | SLC5A11, SLC6A11, SLC5A1 | TLR2 3409/4885CTSS 2079/4885CTSL 876/4885 |
| US-20150152138-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | OPRK1, OGFR, MMP13 | TLR2 118/4885CTSS 155/4885CTSL 357/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | TLR2 787/4885CTSS 329/4885CTSL 495/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | TLR2 686/4885CTSS 516/4885CTSL 646/4885 |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | TLR2 686/4885CTSS 516/4885CTSL 646/4885 |
| US-20190144499-A1 | PHENYL PROPANAMIDE DERIVATIVE, AND MANUFACTURING METHOD AND PHARMACEUTICAL APPLICATION THEREOF | OPRK1, OPRD1, OPRL1 | TLR2 317/4885CTSS 2965/4885CTSL 1700/4885 |
| US-20200368309-A1 | USE OF KOR AGONIST IN COMBINATION WITH MOR AGONIST IN PREPARING DRUG FOR TREATING PAIN | OPRK1, OPRM1, OPRL1 | TLR2 225/4885CTSS 3266/4885CTSL 2790/4885 |
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | OPRK1, OGFR, MMP13 | TLR2 118/4885CTSS 155/4885CTSL 357/4885 |
| US-20200331963-A1 | Salt of phenylpropionamide derivative and preparation method therefor | SLC5A11, HADHA, GOT1 | TLR2 2963/4885CTSS 2816/4885CTSL 2175/4885 |
| US-20110212882-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | OPRK1, OGFR, MMP13 | TLR2 133/4885CTSS 149/4885CTSL 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.